Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition of atenolol/amlodipine/folacin compound and uses thereof

A technology of amlodipine and levamlodipine, which is applied in the field of pharmacy and can solve the problems of reduced cardiac output and coronary flow, coronary blood flow, bleeding and the like

Inactive Publication Date: 2009-04-15
史克勇
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Negative inotropic effects can lead to a decrease in cardiac output and coronary flow, some calcium antagonists also have potential arrhythmogenic effects or a tendency to cause bleeding, and some can cause coronary haemorrhage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of atenolol/amlodipine/folacin compound and uses thereof
  • Pharmaceutical composition of atenolol/amlodipine/folacin compound and uses thereof
  • Pharmaceutical composition of atenolol/amlodipine/folacin compound and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Preparation of Atenolol 20mg / Amlodipine Besylate 2.0mg / Folic Acid 0.4mg Tablets

[0037] prescription

[0038] Atenolol 20g

[0039] Amlodipine Besylate 2.0g

[0040] Folic acid 0.4g

[0041] Starch 45g

[0042] Microcrystalline Cellulose 45g

[0043] Sodium carboxymethylcellulose (CMS.Na) 5.0g

[0044] 5% povidone k-30 (solvent is absolute ethanol) 1.0g

[0045] Magnesium Stearate Appropriate amount

[0046]

[0047] Made into 1000 pieces

[0048] Preparation Process:

[0049] (1) Take the prescribed amount of atenolol, amlodipine besylate and folic acid and pass through a 100-mesh sieve and then mix them uniformly by the method of increasing in equal amounts for subsequent use;

[0050] (2) Other auxiliary materials are passed through a 100-mesh sieve and dried at 75°C for 2 hours;

[0051] (3) Mix the starch, microcrystalline cellulose, and CMS.Na according to the...

Embodiment 2

[0055] Example 2 Preparation of Atenolol 25mg / Amlodipine Maleate 2.5mg / Leucovorin 0.8mg Capsules

[0056] prescription

[0057] Atenolol 25g

[0058] Amlodipine Maleate 2.5g

[0059] Calcium folinate (as folinic acid) 0.8g

[0060] Lactose 30g

[0061] Microcrystalline Cellulose 15g

[0062] Starch 20g

[0063] Carboxymethyl starch sodium 5.0g

[0064] Magnesium Stearate Appropriate amount

[0065]

[0066] Make 1000 capsules

[0067] Preparation Process:

[0068] According to the prescription ratio, take lactose, microcrystalline cellulose, starch, and carboxymethyl starch sodium and dry them at about 100°C for about 2 hours, pass through a 100-mesh sieve; pass the raw material through a 100-mesh sieve, and increase the amount of the above-mentioned excipients in equal increments Mix well and fill the capsules.

[0069] 1 time a day, 1-2 capsules each time.

Embodiment 3

[0070] Example 3 Preparation of Atenolol 50mg / Amlodipine Besylate 5mg / / Folic Acid 0.8mg / Leucovorin 0.8mg Sustained Release Tablets

[0071] prescription

[0072] Atenolol 50g

[0073] Amlodipine Besylate 5g

[0074] Folic acid 0.8g

[0075] Calcium folinate 0.8g

[0076] Citric acid 10g

[0077] Hypromellose (K4M) 160g

[0078] Lactose 180g

[0079] Magnesium Stearate Appropriate amount

[0080]

[0081] Made into 1000 pieces

[0082] Preparation Process:

[0083] According to the proportion of the prescription, the raw material is mixed with hypromellose, citric acid is dissolved in ethanol as a wetting agent to make a soft material, granulated, dried, sized, mixed with magnesium stearate, pressed Slice and serve.

[0084] 1 time every other day, 1 tablet each time.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition containing atenolol, amlodipine, or folic acid compounds and application thereof. The pharmaceutical composition contains an officinal dosage of the atenolol, an officinal dosage of the amlodipine or levamlodipine, an officinal dosage of the folic acid compounds, and a pharmaceutical acceptable carrier. The dosage of the atenolol is between 5 and 50 milligrams, the dosage of the amlodipine or the levamlodipine is between 0.5 and 5.0 milligrams, and the dosage of the folic acid type compounds is between 0.2 and 1.6 milligrams. The pharmaceutical composition has the following advantages: the pharmaceutical composition enhances the hypertension curative effect through multi-target synergistic hypotensive action, and reduces the taking dosage of the amlodipine simultaneously, that is, just about one fourth of the original dosage can achieve the same hypotensive effect and reduce the side effects and medical expenses; and more importantly, the pharmaceutical composition can effectively prevent and treat or delay various complications of high blood pressure cardiovascular and cerebrovascular diseases such as cerebrovascular disorder and the like through dual targets (Hcy and blood pressure) on the basis of reducing toxic side effects. Besides, the pharmaceutical composition ensures that patients can take medicine conveniently.

Description

technical field [0001] The invention relates to a pharmaceutical composition of atenolol / amlodipine / folic acid compound and its application, belonging to the technical field of pharmacy. Background technique [0002] Hypertension is divided into essential hypertension (hypertension, accounting for about 90%) and secondary hypertension (symptomatic hypertension). The prevalence of hypertension is approximately 20% in adults. The direct complications of hypertension include cerebrovascular accident, renal failure, heart failure, etc. Most of these complications can cause disability or death. Generally speaking, the average life expectancy of hypertensive people is 15-20 years shorter than that of normal people. Malignant hypertension, if left untreated, can cause death within a year. The first-line antihypertensive drugs recommended by WHO and my country's hypertension treatment guidelines are: calcium antagonists, RAS inhibitors (including AT1 receptor antagonists and ACE ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4422A61K31/165A61K31/519A61P9/12A61P9/10A61P9/00
Inventor 史克勇徐艺兰苏定冯
Owner 史克勇
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com